Latest news and upcoming events
TiGenix to Raise Capital via a Private Placement of New Ordinary Shares
Leuven, Belgium – July 17, 2013, 18:00h – TiGenix NV (Euronext Brussels: TIG) today announced the launch of a private placement of new ordinary shares for a targeted amount of EUR 5 million.
STAT-Diagnostica Names Gérard Vaillant as Board Chairman
BARCELONA – June 19, 2013 – Medical diagnostics company STAT-Diagnostica has appointed Gérard Vaillant as chairman of the company’s board of directors.
MedLumics appoints Dr. Wolfgang Reim as Independent Director
Madrid, 10th June 2013. MedLumics, a medical imaging company specializing in advanced optical coherence tomography (OCT) technology, has announced the appointment of the industry expert Wolfgang Reim as Independent Director for its board.
TiGenix Business Update & Financial Highlights for Q1 of 2013
Leuven (BELGIUM) – May 14, 2013 –TiGenix NV (Euronext Brussels: TIG), the European leader in cell therapy, gives an update of its business activities and provides the financial highlights for the first quarter ending March 31, 2013.
Endosense underscores significance of contact force parameters with new study data at heart rhythm 2013
GENEVA – May 13, 2013 – Endosense, a pioneer and leader in contact force (CF) technology focused on improving the efficacy and safety of catheter ablation for the treatment of cardiac arrhythmias, further advanced its leadership position in the field with new study data validating the importance of several proprietary contact force parameters, including its most recently developed Lesion Index (LSI™).
Medical Diagnostics Company STAT-Diagnostica Secures 22.1 Million USD/17 Million Euros in Series B Financing
BARCELONA - May 6, 2013 - STAT-Diagnostica has announced the closing of a Series B financing round totaling 22.1 million USD/17 million Euros, the proceeds of which will be used to complete development of the company’s Near Patient Testing diagnostic system and clinical validation of its first products.
TiGenix reports positive Phase IIa study results in refractory rheumatoid arthritis with allogeneic stem cell product Cx611
Leuven (BELGIUM) – April 22, 2013 – TiGenix (NYSE Euronext: TIG), the European leader in cell therapy, today announced positive 6-month safety data of its Phase IIa study of Cx611 in rheumatoid arthritis (RA), as well as a first indication of therapeutic activity on standard outcome measures and biologic markers of inflammation for at least three months after dosing.
Endosense’s efficas i study yields new contact force guidelines in catheter ablation treatmentof af: findings published in circulation: arrhythmia and electrophysiology
GENEVA – March 26, 2013 – Endosense, a pioneer and leader in contact-force sensing technology focused on improving the efficacy and safety of catheter ablation for the treatment of cardiac arrhythmias, has announced that the results of its EFFICAS I prospective multi-center study have led to the development of guidelines for target and minimum contact force (CF), as well as minimum Force Time Integral (FTI™), during the catheter ablation treatment of paroxysmal atrial fibrillation (PAF).
TiGenix to obtain national reimbursement in Spain for its innovative cartilage therapy ChondroCelect®
Leuven (BELGIUM), Madrid (SPAIN) – March 12, 2013 – TiGenix NV (Euronext Brussels: TIG), the European leader in cell therapy, announced today that it was informed by the Spanish Health Authority that its innovative cartilage repair therapy ChondroCelect® will obtain national reimbursement in Spain.
TiGenix Reports Full Year 2012 Financial Results
Leuven (BELGIUM) – March 12, 2013 –TiGenix NV (Euronext Brussels: TIG), the European leader in cell therapy, today gave a business update and announced financial results for the full year 2012.
Subscribe to our weekly newsletter for the latest
updates on life sciences investments.